NBIX
Neurocrine Biosciences Inc
140.70$
-0.8%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | -24.1% | +977.5% | +179.2% | +74.7% | +32.7% | +8.4% | +31.3% | +26.8% | +24.8% | +21.4% | |
| – | +134.7% | +6.2% | -96.5% | +289.9% | +51.4% | +36.5% | +41.6% | +62.2% | +71.1% | -14.4% | +53.2% | |
| – | – | -24.1% | +969.1% | +178.3% | +74.9% | +32.7% | +8.1% | +30.9% | +26.1% | +25.7% | +21.0% | |
| – | +75.5% | +15.7% | -2.6% | +74.8% | +24.6% | +37.5% | +19.3% | +41.4% | +21.8% | +29.4% | +38.9% | |
| – | +80.6% | +109.6% | +149.6% | +46.5% | +42.2% | +22.4% | +34.6% | +29.0% | +13.1% | -4.2% | +41.7% | |
| – | +76.9% | +42.5% | +79.7% | +40.4% | +73.0% | +23.2% | +16.5% | +19.7% | +31.2% | +9.7% | +25.0% | |
| – | – | – | – | – | +96.0% | +125.4% | -37.1% | +142.9% | +0.8% | +127.4% | +8.5% | |
| – | – | – | – | +56.4% | +4.8% | +2.5% | -21.3% | -72.5% | -35.2% | +2,652.2% | – | |
| – | – | – | – | – | +112.9% | +129.5% | -5.0% | +110.9% | +55.3% | +46.3% | +45.1% | |
| – | – | – | – | -95.7% | +1,201.4% | -3,264.2% | – | +403.4% | +38.7% | +75.6% | +56.7% | |
| – | – | – | – | – | +75.3% | +1,000.8% | -78.0% | +72.4% | +61.6% | +36.7% | +40.2% | |
| – | – | – | – | – | +109.9% | +72.4% | -6.8% | +91.6% | +57.3% | +53.7% | +4.2% |
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.